Technology
Health
Pharmaceutical

Sienna Biopharmaceuticals

$1.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-3.76%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SNNA and other stocks, options, ETFs, and crypto commission-free!

About

Sienna Biopharmaceuticals, Inc. Common Stock, also called Sienna Biopharmaceuticals, is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Read More Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Employees
58
Headquarters
Westlake Village, California
Founded
2010
Market Cap
40.06M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
188.79K
High Today
$1.34
Low Today
$1.20
Open Price
$1.31
Volume
44.14K
52 Week High
$18.05
52 Week Low
$1.11

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2017 IPO
US
North America

News

NasdaqMay 9

Sienna Biopharmaceuticals to Present at BAML Health Care Conference

WESTLAKE VILLAGE, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care Conference 2019, Wednesday, May 15, 2019, 3:55 p.m. PDT, in Las Vegas. The presentation will be webcast live and can be accessed through the Investor Relations section of the Company's website at Investors.SiennaB...

104
Yahoo FinanceApr 27

Introducing Sienna Biopharmaceuticals (NASDAQ:SNNA), The Stock That Tanked 90%

It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to avoid stomach churning catastrophes, wherever possible. It must have been painful to be a Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) shareholder over the last year, since the stock price plummeted 90% in that time. While some investors are willing to stomach this sort of loss, they are usually professionals who spread their bets thinly. Sienna Biopharmaceuticals may have better days ahead, o...

227
Simply Wall StApr 25

How Much Of Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) Do Insiders Own?

54

Earnings

-$1.12
-$0.91
-$0.71
-$0.50
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.50 per share
Actual
-$0.67 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.